Elevation Oncology Inc

ELEV08 Dec 2024
Healthcare
$0.62
+0.01 (+1.47%)
Lowest Today
$0.59
Highest Today
$0.63
Today’s Open
$0.62
Prev. Close
$0.59
52 Week High
$5.83
52 Week Low
$0.44
To Invest in Elevation Oncology Inc

Elevation Oncology Inc

Healthcare
ELEV08 Dec 2024
+0.01 (+1.47%)
1M
3M
6M
1Y
5Y
Low
$0.59
Day’s Range
High
$0.63
0.59
52 Week Low
$0.44
52-Week Range
52 Week High
$5.83
0.44
1 Day
-
1 Week
-3.98%
1 month return
-8.14%
3 month return
-3.72%
6 month return
-82.99%
1 Year return
+6.45%
3 Years return
-88.71%
5 Years return
-
10 Years return
-
Institutional Holdings
TANG CAPITAL MANAGEMENT LLC
8.05
Goldman Sachs Group Inc
6.75
Farallon Capital Management, L.L.C.
5.97
Vanguard Group Inc
5.2
Bvf Inc
5.02
Aisling Capital Management LP
4.8
BlackRock Inc
4.21

Market Status

Fundamentals
Market Cap
35.47 mln
PB Ratio
0.51
PE Ratio
0
Enterprise Value
-36.58 mln
Total Assets
89.09 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.
Organisation
Elevation Oncology Inc
Employees
29
Industry
Biotechnology
CEO
Mr. Joseph J. Ferra Jr.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities